BeiGene revela proposta de mudana de nome para BeOne Medicines, reafirmando sua misso de unir a comunidade global contra o cncer
BGNE Stock | USD 206.16 14.05 7.31% |
About 54% of BeiGene's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding BeiGene suggests that some traders are interested. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
A BeiGene, Ltd. , uma empresa global de oncologia, anunciou hoje sua inteno de mudar o nome da empresa para
Read at businesswire.com
BeiGene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
BeiGene is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
IMVT | Immunovant | 5.78 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
AKRO | Akero Therapeutics | 3.24 | ||||
PCVX | Vaxcyte | 2.77 | ||||
IONS | Ionis Pharmaceuticals | 1.50 | ||||
LEGN | Legend Biotech | 1.29 | ||||
ASND | Ascendis Pharma | 1.28 | ||||
IMAB | I Mab | 1.06 | ||||
ARWR | Arrowhead Pharmaceuticals | 1.03 | ||||
INCY | Incyte | 0.87 | ||||
BMRN | Biomarin Pharmaceutical | 0.83 | ||||
BPMC | Blueprint Medicines | 0.50 | ||||
KRYS | Krystal Biotech | 0.20 | ||||
TVTX | Travere Therapeutics | 1.89 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |